Victory Capital Management Inc Akero Therapeutics, Inc. Transaction History

Victory Capital Management Inc

$92 Billion
Q1 2025

A detailed history of Victory Capital Management Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 35,116 shares of AKRO stock, worth $1.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,116

Previous 7,235 385.36%

Holding current value

$1.69 Million

Previous $201,000 606.97%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 02, 2025	BUY	$21.87 - $57.56 $609,757 - $1.6 Million	27,881 Added 385.36%	35,116 $1.42 Million
Q4 2024 Feb 06, 2025	SELL	$26.75 - $35.28 $3,611 - $4,762	-135 Reduced 1.83%	7,235 $201,000
Q3 2024 Nov 05, 2024	BUY	$21.45 - $29.34 $158,086 - $216,235	7,370 New	7,370 $211,000
Q4 2023 Feb 05, 2024	SELL	$11.38 - $50.33 $2.04 Million - $9.04 Million	-179,572 Reduced 92.83%	13,880 $324,000
Q3 2023 Nov 06, 2023	SELL	$41.19 - $52.25 $4.29 Million - $5.44 Million	-104,120 Reduced 34.99%	193,452 $9.78 Million
Q2 2023 Jul 27, 2023	BUY	$36.89 - $56.88 $3.47 Million - $5.35 Million	93,990 Added 46.17%	297,572 $13.9 Million
Q1 2023 May 02, 2023	BUY	$37.27 - $50.24 $7.44 Million - $10 Million	199,495 Added 4881.21%	203,582 $7.79 Million
Q4 2022 Feb 10, 2023	BUY	$33.44 - $54.8 $1,237 - $2,027	37 Added 0.91%	4,087 $223,000
Q4 2022 Feb 09, 2023	SELL	$33.44 - $54.8 $507,084 - $830,987	-15,164 Reduced 78.92%	4,050 $221,000
Q3 2022 Nov 02, 2022	SELL	$10.15 - $34.05 $7,125 - $23,903	-702 Reduced 3.52%	19,214 $654,000
Q2 2022 Aug 01, 2022	SELL	$8.0 - $15.01 $80 - $150	-10 Reduced 0.05%	19,916 $188,000
Q1 2022 May 04, 2022	BUY	$12.97 - $22.26 $9,299 - $15,960	717 Added 3.73%	19,926 $209,000
Q4 2021 Feb 07, 2022	SELL	$19.87 - $26.24 $54,900 - $72,501	-2,763 Reduced 12.58%	19,209 $406,000
Q3 2021 Nov 02, 2021	BUY	$18.65 - $25.46 $578 - $789	31 Added 0.14%	21,972 $491,000
Q2 2021 Aug 03, 2021	SELL	$24.81 - $32.35 $25,331 - $33,029	-1,021 Reduced 4.45%	21,941 $544,000
Q1 2021 May 04, 2021	SELL	$24.04 - $34.19 $25,434 - $36,173	-1,058 Reduced 4.4%	22,962 $666,000
Q4 2020 Feb 01, 2021	SELL	$25.12 - $29.89 $25,672 - $30,547	-1,022 Reduced 4.08%	24,020 $620,000
Q3 2020 Nov 09, 2020	SELL	$30.79 - $39.92 $266,826 - $345,946	-8,666 Reduced 25.71%	25,042 $771,000
Q2 2020 Aug 07, 2020	SELL	$19.25 - $26.76 $4,543 - $6,315	-236 Reduced 0.7%	33,708 $840,000
Q1 2020 May 04, 2020	BUY	$12.8 - $27.05 $413,900 - $874,688	32,336 Added 2010.95%	33,944 $720,000
Q4 2019 Feb 06, 2020	SELL	$17.37 - $27.27 $565,845 - $888,347	-32,576 Reduced 95.3%	1,608 $36,000
Q4 2019 Feb 04, 2020	BUY	$17.37 - $27.27 $548,110 - $860,504	31,555 Added 1200.27%	34,184 $844,000
Q3 2019 Nov 12, 2019	BUY	$16.89 - $29.88 $17,244 - $30,507	1,021 Added 63.5%	2,629 $60,000
Q2 2019 Aug 15, 2019	BUY	$18.08 - $19.83 $29,072 - $31,886	1,608 New	1,608 $31,000

Others Institutions Holding AKRO

# of Institutions

270

Shares Held

86M

Call Options Held

1.02M

Put Options Held

823K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.24B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account

Victory Capital Management Inc Akero Therapeutics, Inc. Transaction History